全文获取类型
收费全文 | 1352篇 |
免费 | 107篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 74篇 |
妇产科学 | 46篇 |
基础医学 | 195篇 |
口腔科学 | 13篇 |
临床医学 | 105篇 |
内科学 | 251篇 |
皮肤病学 | 15篇 |
神经病学 | 118篇 |
特种医学 | 198篇 |
外科学 | 122篇 |
综合类 | 20篇 |
预防医学 | 88篇 |
眼科学 | 51篇 |
药学 | 53篇 |
1篇 | |
中国医学 | 7篇 |
肿瘤学 | 97篇 |
出版年
2023年 | 9篇 |
2022年 | 9篇 |
2021年 | 20篇 |
2020年 | 10篇 |
2019年 | 27篇 |
2018年 | 39篇 |
2017年 | 17篇 |
2016年 | 18篇 |
2015年 | 18篇 |
2014年 | 38篇 |
2013年 | 52篇 |
2012年 | 71篇 |
2011年 | 70篇 |
2010年 | 49篇 |
2009年 | 47篇 |
2008年 | 65篇 |
2007年 | 72篇 |
2006年 | 55篇 |
2005年 | 36篇 |
2004年 | 28篇 |
2003年 | 27篇 |
2002年 | 24篇 |
2001年 | 27篇 |
2000年 | 23篇 |
1999年 | 22篇 |
1998年 | 36篇 |
1997年 | 32篇 |
1996年 | 43篇 |
1995年 | 44篇 |
1994年 | 40篇 |
1993年 | 27篇 |
1992年 | 17篇 |
1991年 | 17篇 |
1989年 | 27篇 |
1988年 | 45篇 |
1987年 | 35篇 |
1986年 | 15篇 |
1985年 | 23篇 |
1984年 | 16篇 |
1983年 | 12篇 |
1982年 | 10篇 |
1981年 | 12篇 |
1980年 | 14篇 |
1979年 | 13篇 |
1978年 | 10篇 |
1977年 | 12篇 |
1976年 | 9篇 |
1974年 | 10篇 |
1972年 | 11篇 |
1971年 | 9篇 |
排序方式: 共有1468条查询结果,搜索用时 15 毫秒
41.
42.
43.
Tumor volume as a predictor of survival in human papillomavirus–positive oropharyngeal cancer
下载免费PDF全文
![点击此处可从《Head & neck》网站下载免费的PDF全文](/ch/ext_images/free.gif)
44.
45.
On the use of the not‐at‐random fully conditional specification (NARFCS) procedure in practice
下载免费PDF全文
![点击此处可从《Statistics in medicine》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Daniel Mark Tompsett Finbarr Leacy Margarita Moreno‐Betancur Jon Heron Ian R. White 《Statistics in medicine》2018,37(15):2338-2353
The not‐at‐random fully conditional specification (NARFCS) procedure provides a flexible means for the imputation of multivariable missing data under missing‐not‐at‐random conditions. Recent work has outlined difficulties with eliciting the sensitivity parameters of the procedure from expert opinion due to their conditional nature. Failure to adequately account for this conditioning will generate imputations that are inconsistent with the assumptions of the user. In this paper, we clarify the importance of correct conditioning of NARFCS sensitivity parameters and develop procedures to calibrate these sensitivity parameters by relating them to more easily elicited quantities, in particular, the sensitivity parameters from simpler pattern mixture models. Additionally, we consider how to include the missingness indicators as part of the imputation models of NARFCS, recommending including all of them in each model as default practice. Algorithms are developed to perform the calibration procedure and demonstrated on data from the Avon Longitudinal Study of Parents and Children, as well as with simulation studies. 相似文献
46.
47.
Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations
下载免费PDF全文
![点击此处可从《Annals of neurology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Ingrid E. Scheffer MB BS PhD Sarah E. Heron BSc PhD Brigid M. Regan BSc Simone Mandelstam MB ChB Douglas E. Crompton MBBS PhD Bree L. Hodgson Dip Biomed Sci Laura Licchetta MD Federica Provini MD PhD Francesca Bisulli MD PhD Lata Vadlamudi MB BS PhD Jozef Gecz PhD Alan Connelly PhD Paolo Tinuper MD Michael G. Ricos BSc PhD Samuel F. Berkovic MD FRS Leanne M. Dibbens BSc PhD 《Annals of neurology》2014,75(5):782-787
We recently identified DEPDC5 as the gene for familial focal epilepsy with variable foci and found mutations in >10% of small families with nonlesional focal epilepsy. Here we show that DEPDC5 mutations are associated with both lesional and nonlesional epilepsies, even within the same family. DEPDC5‐associated malformations include bottom‐of‐the‐sulcus dysplasia (3 members from 2 families), and focal band heterotopia (1 individual). DEPDC5 negatively regulates the mammalian target of rapamycin (mTOR) pathway, which plays a key role in cell growth. The clinicoradiological phenotypes associated with DEPDC5 mutations share features with the archetypal mTORopathy, tuberous sclerosis, raising the possibility of therapies targeted to this pathway. Ann Neurol 2014;75:782–787 相似文献
48.
Arends RJ Rotllant J Metz JR Mancera JM Wendelaar Bonga SE Flik G 《The Journal of endocrinology》2000,166(2):427-435
MSH is a pituitary hormone derived by post-translational processing from POMC and involved in stress and background adaptation. N-terminal acetylation of MSH to monoacetyl alpha-MSH or diacetyl alpha-MSH increases the bioactivity of the peptide. The aim of this study was to characterize alpha-MSH acetylation in the sea bream (Sparus aurata L.) pituitary gland in response to the stressors air exposure and confinement, as well as in fish adapted for 15 days to a white, gray or black background. Pituitary homogenates were purified by reversed-phase HPLC (RP-HPLC). The alpha-MSH content of fractions was measured by RIA. Immunoreactive RP-HPLC fractions were further analyzed by electrospray mass spectrometry and the peptide sequence determined as SYSMEHFRWGKPV-NH2. In the pituitary gland of sea bream, des-, mono- and diacetyl alpha-MSH were identified. Then plasma alpha-MSH levels were measured in sea bream adapted to different backgrounds. Surprisingly, we found the highest plasma alpha-MSH levels in white-adapted as compared with black-adapted sea bream with intermediate values for gray-adapted fish. This observation is in contrast with results that have been obtained in eel, trout or terrestrial vertebrates. Next, des-, mono- and diacetyl alpha-MSH forms were measured in homogenates of the pituitary gland and in plasma of sea bream exposed to air, to confinement, or to different backgrounds. Monoacetyl alpha-MSH was the predominant form in all control and experimental groups. The lowest content of monoacetyl alpha-MSH relative to des- and diacetyl alpha-MSH was found in white-adapted fish. Levels of des- and diacetyl alpha-MSH forms were similar under all conditions. We observed that monoacetyl alpha-MSH is the most abundant isoform in the pituitary gland after background adaptation, confinement and air exposure, in sea bream. These data indicate that the physiologically most potent isoform of alpha-MSH may vary from species to species. 相似文献
49.
50.
Transforming growth factor beta (TGF-beta) is a potent and selective growth inhibitor of early hematopoietic progenitors and leukemic cells. The cellular mechanism(s) underlying this antiproliferative effect is, however, currently unknown. In the present study, we demonstrate that TGF-beta inhibits the expression of granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin 3 (IL-3), and granulocyte-CSF (G-CSF) receptors on murine factor-dependent and independent hematopoietic progenitor cell lines without a significant change in receptor affinity. A maximum reduction in GM-CSF receptor numbers of 65% to 77% was observed by 96-hour incubation with TGF-beta. The TGF- beta induced trans-down-modulation of GM-CSF receptors was prolonged, noncytotoxic but reversible, and not due to endogenous production of GM- CSF. The TGF-beta induced reduction in CSF receptor numbers preceded TGF-beta's growth inhibitory action. In addition, the ED50 (1 to 10 pmol/L) for TGF-beta's CSF receptor modulatory and antiproliferative effect was similar. The effect of TGF-beta on cell surface CSF receptor expression was specific, because the expression of other cell surface proteins (Ly 5 and Ly 17) was not affected by TGF-beta treatment, and because other growth inhibitors (tumor necrosis factor and interferon) did not affect CSF receptor expression. These data suggest that the downregulation of the growth of hematopoietic progenitor cells by TGF- beta involves reducing the cell surface expression on growth factor receptors. 相似文献